Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$449.1K-8.54%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Mark A. Emalfarb
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5
- Beta
- 1.08
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -18.86
Financials
Revenue
$449.1K-8.5%Net Income
$-1.36MEBITDA
$-1.81MFree Cash Flow
$-1.48MEPS (diluted)
$-0.04Shares Outstanding (diluted)
38.29M+5.8%Operating Expenses
$1.61MCash & Debt
$4.57MReturn of Capital
$0.00Revenue by Segment (annual)
$3.09MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.23M | $-7.36M | $-0.23 |
| 2024 | $3.50M | $-5.81M | $-0.20 |
| 2023 | $2.90M | $-6.80M | $-0.24 |
| 2022 | $2.93M | $-9.74M | $-0.34 |
| 2021 | $2.40M | $-13.07M | $-0.47 |
| 2020 | $1.60M | $-9.33M | $-0.34 |
| 2019 | $1.68M | $-8.31M | $-0.31 |
| 2018 | $1.30M | $-5.69M | $-0.21 |
| 2017 | $758.4K | $-2.14M | $-0.07 |
| 2016 | $592.9K | $-3.61M | $-0.10 |
| 2015 | $315.7K | $65.79M | $1.91 |
| 2014 | $12.52M | $-5.98M | $-0.18 |
| 2013 | $17.13M | $-428.1K | $-0.01 |
| 2012 | $15.60M | $1.35M | $0.04 |
Valuation
DYAIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
110-8.33%Social Signal Score
Mentions (6)
- Newsfool.com·9d ago·Positive
Dyadic: 3 Key Takeaways for Long-Term Investors Third-quarter revenue decreased 61% year over year to $449,000. Gates-funded antibody programs achieved yields of 12.1 grams per liter.
View source ↗ - Newsglobenewswire.com·10d ago·Positive
…l Studies Following Positive Independent Evaluations JUPITER, Fla., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI), operating as Dyadic Applied BioSolutions, today announced that the Gates Medical Research Institute has initiated preclinical animal studies comparing monoclonal antibodies (mAbs) against respiratory syncytial virus (RSV) and malaria, produced using Dyadic's proprietary C1 protein production platform, with their respective ma…
View source ↗ - Newsglobenewswire.com·23d ago·Negative
…UPITER, Fla., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results …
View source ↗ - Newsseekingalpha.com·68d ago·Positive
Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript
View source ↗ - Newsseekingalpha.com·101d ago·Positive
Dyadic International, Inc. (DYAI) Q2 2026 Earnings Call Transcript Dyadic International, Inc. (DYAI) Q2 2026 Earnings Call Transcript
View source ↗ - Newsglobenewswire.com·102d ago·Negative
Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas JUPITER, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today reported its financial results for the second quarter ended June
View source ↗
Earnings
Wed, Mar 24(in 4 months)
Consensus estimate $-0.02 per share
Typical surprise -37.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 12$-0.05 vs $-0.04miss
- Wed, Aug 12$-0.06 vs $-0.04miss
- Wed, May 13$-0.05 vs $-0.04miss
- Wed, Mar 25$-0.06 vs $-0.03miss
- Wed, Nov 12$-0.06 vs $-0.04miss
- Wed, Aug 13$-0.06 vs $-0.06beat
Estimates and results for DYAI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DYAI officers and directors.
- Bought
- $1.0m
- Sold
- $469k
2 trades
10 trades
- Francisco Trust Under Agreement Dated February 28, 1996sold
- Francisco Trust Under Agreement Dated February 28, 1996sold
- Francisco Trust Under Agreement Dated February 28, 1996sold
- Hazelton Joseph Pbought
- Francisco Trust Under Agreement Dated February 28, 1996sold
- Francisco Trust Under Agreement Dated February 28, 1996sold
- Francisco Trust Under Agreement Dated February 28, 1996sold
- Francisco Trust Under Agreement Dated February 28, 1996sold
87 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in DYAI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
